Paving the way to better care
A public-private international research collaboration aiming to personalise prevention and treatment of cardiovascular disease.
The challenge of cardiovascular disease
Cardiovascular disease (CVD) is a highly prevalent disease that poses challenges to healthcare systems worldwide. In Europe alone, it affects over 85 million people – a number that is rising due to an aging population and unhealthy lifestyles.
Despite medical advancements, treating CVD effectively remains challenging due to the complex interplay of risk factors and co-existing conditions in patients, such as diabetes and hypertension.
While a “one size fits all” approach persists, the diverse nature of CVD calls for personalized treatment strategies that improve care for patients. That’s the ultimate goal of iCARE4CVD.
Number of people affected by CVD
> 500 million worldwide
Number of people that die from CVD
~ 17 million worldwide
From one-size-fits-all to personalised care
By creating one database gathering data from more than 1 million patients and using artificial intelligence, iCARE4CVD will look for new strategies to shift from a one-size-fits-all approach to personalised care.
The project will focus on improving four key areas of current CVD healthcare by:
- Enhancing early diagnosis of patients at risk with cardiovascular disease
- Developing and assign risk levels to patients, defining those who need urgent intervention
- Predict how individuals will respond to treatment through the application of AI-based tools
- Ensure the inclusion of patient-supported outcomes by incorporating their unique perspectives into every area of our work
34 leading partners
from civil society, academia, and industry
22 million EUR
in funding
4.5 years
of project duration
Our latest news
iCARE4CVD partners
iCARE4CVD brings together 33 leading international partners from civil society, academia and industry, and is lead by Maastricht University and global
healthcare company Novo Nordisk.
Subscribe to our newsletter
Subscribe to our newsletter
And up to speed with all our most recent developments
